The effects of the multispecies probiotic mixture Ecologic®Barrier on migraine: Results of an open-label pilot study

Beneficial Microbes

Volumn 6, Issue 5, 2015, Pages 641-646

  de Roos, N M ^a   Giezenaar, C G T ^a   Rovers, J M P ^b   Witteman, B J M ^b   Smits, M G ^b   van Hemert, S ^c  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b GELDERSE VALLEI HOSPITAL   (Netherlands)

^c WINCLOVE PROBIOTICS   (Netherlands)

Author keywords

Feasibility; Gut permeability; Headache; Intestine; Leaky gut; Migraine; Probiotics

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; PARACETAMOL; PROBIOTIC AGENT; TRIPTAN DERIVATIVE;

ADULT; ARTICLE; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM BIFIDUM; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BREVIS; LACTOBACILLUS CASEI; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; MALE; MIGRAINE; PAIN ASSESSMENT; PAIN INTENSITY; PILOT STUDY; PREVALENCE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; INCIDENCE; MIGRAINE DISORDERS; PATHOLOGY;

HUMANS; INCIDENCE; MIGRAINE DISORDERS; PILOT PROJECTS; PROBIOTICS; TREATMENT OUTCOME;

EID: 84944393198     PISSN: 18762883     EISSN: 18762891     Source Type: Journal    
DOI: 10.3920/BM2015.0003     Document Type: Article

References (44)

1. Anderson, R.C., Cookson, A.L., McNabb, W.C., Kelly, W.J. and Roy, N.C., 2010. Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. FEMS Microbiology Letters 309: 184-192.
2. Bensenor, I.M., Cook, N.R., Lee, I.M., Chown, M.J., Hennekens, C.H. and Buring, J.E., 2001. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia 21: 175-183.
3. Bussone, G., Diener, H.C., Pfeil, J. and Schwalen, S., 2005. Topiramate 100 mg/day in migraine prevention: a pooled analysis of doubleblind randomised controlled trials. International Journal of Clinical Practice 59: 961-968.
4. Covelli, V., Pellegrino, N.M. and Jirillo, E., 2003. A point of view: The need to identify an antigen in psyconeuroimmunological disorders. Current Pharmaceutical Design 9: 1951-1955.
5. D'Souza, A.L., Rajkumar, C., Cooke, J. and Bulpitt, C.J., 2002. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 324: 1361.
6. De Groot, F.M., Voogt-Bode, A., Passchier, J., Berger, M.Y., Koes, B.W. and Verhagen, A.P., 2011. Headache: the placebo effects in the control groups in randomized clinical trials; an analysis of systematic reviews. Journal of Manipulative and Physiological Therapeutics 34: 297-305.
7. Diener, H.C., Tfelt-Hansen, P., Dahlof, C., Lainez, M.J., Sandrini, G., Wang, S.J., Neto, W., Vijapurkar, U., Doyle, A., Jacobs, D. and Group, M.-S., 2004. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. Journal of Neurology 251: 943-950.
8. Duerksen, D.R., Wilhelm-Boyles, C. and Parry, D.M., 2005. Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet. Digestive Diseases and Sciences 50: 785-790.
9. Elsenbruch, S., Schmid, J., Basler, M., Cesko, E., Schedlowski, M. and Benson, S., 2012. How positive and negative expectations shape the experience of visceral pain: an experimental pilot study in healthy women. Neurogastroenterology and Motility 24: 914-e460.
10. Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2001. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Available at: http://tinyurl.com/8bccc3r.
11. Gales, B.J., Bailey, E.K., Reed, A.N. and Gales, M.A., 2010. Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Annals of Pharmacotherapy 44: 360-366.
12. Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology 11: 506-514.
13. Holroyd, K.A., Penzien, D.B. and Cordingley, G.E., 1991. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31: 333-340.
14. Hoveyda, N., Heneghan, C., Mahtani, K., Perera, R., Roberts, N. and Glasziou, P., 2009. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology 9: 15.
15. Hungin, A.P., Mulligan, C., Pot, B., Whorwell, P., Agreus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.M., Rubin, G., Winchester, C. and de Wit, N., 2013. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidence-based international guide. Alimentary Pharmacology and Therapeutics 38: 864-886.
16. Jacobson, G.P., Ramadan, N.M., Aggarwal, S.K. and Newman, C.W., 1994. The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology 44: 837-842.
17. Kerckhoffs, A.P.M., Akkermans, L.M.A., de Smet, M.B.M., Besselink, M.G.H., Hietbrink, F., Bartelink, I.H., Busschers, W.B., Samsom, M. and Renooij, W., 2010. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Digestive Diseases and Sciences 55: 716-723.
18. Koning, C.J., Jonkers, D.M., Stobberingh, E.E., Mulder, L., Rombouts, F.M. and Stockbrugger, R.W., 2008. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. American Journal of Gastroenterology 103: 178-189.
19. Lamprecht, M., Bogner, S., Schippinger, G., Steinbauer, K., Fankhauser, F., Hallstroem, S., Schuetz, B. and Greilberger, J.F., 2012. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. Journal of the International Society of Sports Nutrition 9: 45.
20. Launer, L.J., Terwindt, G.M. and Ferrari, M.D., 1999. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 53: 537-542.
21. Liévin, V., Peiffer, I., Hudault, S., Rochat, F., Brassart, D., Neeser, J.-R. and Servin, A.L., 2000. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 47: 646-652.
22. Macedo, A., Banos, J.E. and Farre, M., 2008. Placebo response in the prophylaxis of migraine: A meta-analysis. European Journal of Pain 12: 68-75.
23. Mennigen, R. and Bruewer, M., 2009. Effect of probiotics on intestinal barrier function. Annals of the New York Academy of Sciences 1165: 183-189.
24. Miyauchi, E., O'Callaghan, J., Butto, L.F., Hurley, G., Melgar, S., Tanabe, S., Shanahan, F., Nally, K. and O'Toole, P.W., 2012. Mechanism of protection of transepithelial barrier function by Lactobacillus salivarius: strain-dependence and attenuation by bacteriocin production. American Journal of Physiology-Gastrointestinal and Liver Physiology 303: G1029-G1041.
25. Monteith, T. and Goadsby, P., 2011. Acute migraine therapy: new drugs and new approaches. Current Treatment Options in Neurology 13: 1-14.
26. Neeser, J.-R., Granato, D., Rouvet, M., Servin, A., Teneberg, S. and Karlsson, K.-A., 2000. Lactobacillus johnsonii La1 shares carbohydrate-binding specificities with several enteropathogenic bacteria. Glycobiology 10: 1193-1199.
27. Niers, L., Martin, R., Rijkers, G., Sengers, F., Timmerman, H., van Uden, N., Smidt, H., Kimpen, J. and Hoekstra, M., 2009. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy 64: 1349-1358.
28. Ohland, C.L. and Macnaughton, W.K., 2010. Probiotic bacteria and intestinal epithelial barrier function. American Journal of Physiology-Gastrointestinal and Liver Physiology 298: G807-819.
29. Parlesak, A., Schafer, C., Schutz, T., Bode, J.C. and Bode, C., 2000. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. Journal of Hepatology 32: 742-747.
30. Persborn, M., Gerritsen, J., Wallon, C., Carlsson, A., Akkermans, L.M. and Soderholm, J.D., 2013. The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics 38: 772-783.
31. Pfaffenrath, V., Diener, H.C., Fischer, M., Friede, M., Henneicke-von Zepelin, H.H. and Investigators, 2002. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis-a double-blind, multicentre, randomized placebo-controlled doseresponse study. Cephalalgia 22: 523-532.
32. Piche, T., Barbara, G., Aubert, P., des Varannes, S.B., Dainese, R., Nano, J.L., Cremon, C., Stanghellini, V., De Giorgio, R., Galmiche, J.P. and Neunlist, M., 2009. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58: 196-201.
33. Reid, G., Gaudier, E., Guarner, F., Huffnagle, G.B., Macklaim, J.M., Munoz, A.M., Martini, M., Ringel-Kulka, T., Sartor, B., Unal, R., Verbeke, K. and Walter, J., 2010. Responders and non-responders to probiotic interventions: how can we improve the odds? Gut Microbes 1: 200-204.
34. Salim, S.Y. and Soderholm, J.D., 2011. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflammatory Bowel Diseases 17: 362-381.
35. Samsam, M., Covenas, R., Ahangari, R. and Yajeya, J., 2010. Neuropeptides and other chemical mediators, and the role of antiinflammatory drugs in primary headaches. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry 9: 170-188.
36. Scaldaferri, F., Pizzoferrato, M., Gerardi, V., Lopetuso, L. and Gasbarrini, A., 2012. The gut barrier: new acquisitions and therapeutic approaches. Journal of Clinical Gastroenterology 46 Suppl.: S12-17.
37. Schellenberg, R., Lichtenthal, A., Wohling, H., Graf, C. and Brixius, K., 2008. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? Headache 48: 118-125.
38. Sensenig, J., Johnson, M. and Staverosky, T., 2001. Treatment of migraine with targeted nutrition focused on improved assimilation and elimination. Alternative Medicine Review 6: 488-494.
39. Shuhendler, A.J., Lee, S., Siu, M., Ondovcik, S., Lam, K., Alabdullatif, A., Zhang, X., Machado, M. and Einarson, T.R., 2009. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebocontrolled trials. Pharmacotherapy 29: 784-791.
40. Stewart, W.F., Lipton, R.B., Whyte, J., Dowson, A., Kolodner, K., Liberman, J.N. and Sawyer, J., 1999. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53: 988-994.
41. Van Hemert, S., Breedveld, A., Rovers, J., Vermeiden, J., Witteman, B., Smits, M. and de Roos, N., 2014. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Frontiers in Neurology 5: 241.
42. Waeber, C. and Moskowitz, M.A., 2005. Migraine as an inflammatory disorder. Neurology 64: S9-15.
43. Wang, S.J., Chen, P.K. and Fuh, J.L., 2010. Comorbidities of migraine. Frontiers in Neurology 1: 16.
44. Wang, X., Shang, D., Ribbing, J., Ren, Y., Deng, C., Zhou, T., Guo, F. and Lu, W., 2012. Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second. European Journal of Clinical Pharmacology 68: 1157-1166.